New therapeutic options to manage difficult to control asthma
Price: FREE for members and non-members
Session recorded on November 11, 2021
Speaker: Shahzad Mustafa, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this activity learners should be able to:
1.Identify new therapies for asthma
2. Identify when to consider new therapies for asthma
3. Identify the best candidates for the new asthma therapies
All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Shahzad Mustafa, MD, Speaker
Disclosures: Speaker: Genentech, Regeneron, GSK, AstraZeneca, CSL Behring
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance